Tony Fong is managing editor for 360Dx, GenomeWeb's news site on the in vitro diagnostics market.
The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
PerkinElmer is providing its recently FDA-approved test for the program, which has identified one baby, so far, as positive for DMD.
The IVD industry is optimistic that political tensions between the US and China won't slow down their businesses. However, other challenges may lay ahead for them.
The company formally debuted the DxA 5000 at EuroMedLab 2019 this week as management pointed to its importance in the rejuvenation to the firm's pipeline.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
Researchers at NJIT have initially tested their biochip for the detection of early-stage ovarian cancer, but they said it could have use for other cancers and diseases.
The University of Illinois team developed the technology with an eye at low-resource settings, including developing nations and rural communities.